Trial Profile
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Acute lung injury; Adult respiratory distress syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 06 Nov 2014 New trial record